Organon rose 16.9% today, as the market prices in rumors of a roughly $10 billion acquisition bid. It is reported that Taiyuan Pharmaceutical and multiple parties are bidding, with some Call options surging 173%.
Organon was spun off from Merck, with debt of around $8.6 billion, but its stable cash flow from generic drugs and women's health products makes it a privatization target.
Considering the median M&A premium in the pharmaceutical industry over the past 18 months was above 30%, the current market cap is attractive to potential bidders.
Antitrust risks at the regulatory level are relatively manageable, as Organon has no significant overlap with major pharmaceutical companies. If this news materializes, $10 billion is a price range acquirers can afford.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
